

Access to personal protective equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: a population-based case-control study in six countries

Hyunju Kim,^{1,2} Sheila Hegde,^{3,4} Christine LaFiura,⁵ Madhunika Raghavan,⁵ Nancy Sun,⁶ Susan Cheng,⁶ Casey M Rebholz,^{1,2} Sara B Seidelmann^{4,7,8}

To cite: Kim H, Hegde S, LaFiura C, *et al.* Access to personal protective equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: a population-based case-control study in six countries. *BMJ Global Health* 2021;**6**:e004611. doi:10.1136/bmjgh-2020-004611

Handling editor Seye Abimbola

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2020-004611>).

Received 1 December 2020
Revised 5 January 2021
Accepted 14 January 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Sara B Seidelmann;
smb88@caa.columbia.edu

ABSTRACT

Background Despite the widespread implementation of personal protective equipment (PPE) in the COVID-19 pandemic, there are surprisingly few studies of its impact. To assess the risk, severity and duration of COVID-19 in relation to access to PPE in at-risk healthcare workers (HCWs).

Methods From 17 July to 25 September 2020, at-risk physicians and nurses registered as a provider in the Survey Healthcare Globus network in six countries (the UK, Germany, France, Italy, Spain and USA) were identified based on adult medical specialties with frequent and close contact with patients with COVID-19. Exposed HCWs completed a detailed questionnaire including demographics, medical, social and lifestyle factors. COVID-19 cases were defined as COVID-19 symptoms (fever, cough, fatigue, loss of taste or smell) and asymptomatic COVID-19 test positive cases.

Results Among 2884 exposed HCWs (94% medical doctors and 6% nurses or physician assistants), there were 514 reports of COVID-19 illness and 54 asymptomatic COVID-19 test positive cases. COVID-19 risk was significantly associated with close contact with COVID-19 cases both inside and outside the workplace, number of work shifts and hours worked per week. Limited access to PPE compared with access to a fresh mask, gown and gloves and face shield with each patient encounter was associated with a 2.2-fold to 22-fold increased risk of reporting COVID-19 symptoms ($p<0.0001$), a pattern consistent across all six countries. Further, limited access to PPE was associated with symptom duration greater than 2 weeks and the presence of moderate to severe symptoms such as difficulty breathing, abnormal chest X-ray, low oxygen saturations, respiratory distress and acute lung injury.

Conclusion In six countries, less access to PPE was strongly associated with both increased risk of reporting COVID-19 illness as well as more prolonged and severe disease course in frontline HCWs.

INTRODUCTION

Healthcare workers (HCWs) have been disproportionately affected by the COVID-19 pandemic, caused by the novel coronavirus,

Key questions

What is already known?

- Healthcare workers (HCWs) have been disproportionately affected by the COVID-19 pandemic, caused by the novel coronavirus, SARS-CoV-2.
- Despite the widespread implementation of personal protective equipment (PPE) in the COVID-19 pandemic, there are surprisingly few studies of its impact.
- More evidence is needed to understand the effect of PPE on COVID-19 disease transmission and disease course.

What are the new findings?

- Limited access to PPE compared with access to a fresh mask, gown and gloves and face shield with each patient encounter was associated with a significantly increased risk of reporting COVID-19 symptoms in the UK, Germany, France, Italy, Spain and USA.
- Limited access to PPE was associated with increased severity of the disease and the presence of moderate to severe symptoms such as difficulty breathing, abnormal chest X-ray, low oxygen saturations, respiratory distress and acute lung injury.

What do the new findings imply?

- Our findings highlight the need for excellent access to PPE in frontline HCWs.
- Greater access to PPE was associated with shorter and less severe illness, supporting the idea that even when PPE fails, it may reduce the dose of virus taken in by the mask-wearer and offer protection from severe illness.

SARS-CoV-2.¹ Given their high frequency of exposure, HCWs who treat adult patients with COVID-19 illness in emergency rooms and hospitals may be particularly susceptible to contracting the infection.² Despite the widespread implementation of personal

protective equipment (PPE) during the COVID-19 pandemic, there are surprisingly few studies of its impact.^{1,3}

To date, only a few observational studies in HCWs and non-HCWs and one randomised controlled trial in non-HCWs have been published on the effectiveness of PPE and COVID-19 infection. A meta-analysis on face mask use, eye protection and viral infections found that face masks were associated with an 82% lower risk and eye protection was associated with a 75% lower risk of SARS, Middle East respiratory syndrome, and COVID-19 collectively. However, the meta-analysis included only three studies of COVID-19 and facemasks, two of which were small with 10 events or fewer, and no studies were included for COVID-19 and eye protection.⁴ In a large US academic medical centre, requiring mask wearing for all employees and patients resulted in a significant decrease in transmission between patients and HCWs and among HCWs.⁵ Other centres have not been as fortunate to have sufficient PPE with HCWs resorting to reusing single use PPE or developing makeshift alternatives.⁶ Meta-analyses of the prevention of infectious diseases with PPE have suggested its benefit but called for more work in the field.⁷ Since publication of these studies, one randomised controlled trial in Denmark examined whether a recommendation to wear a mask reduced incident SAR-CoV-2 infection among mask wearers in the general community.⁸ This trial found that the incidence of SAR-CoV-2 infection did not differ for participants who were recommended to wear masks compared with those who were not. However, recommendations to wear masks does not necessarily indicate that participants actually wore masks and behaviours may have differed among mask wearers vs non-mask wearers. Given the limited evidence base, more studies are needed to understand the effect of PPE on COVID-19 disease transmission and disease course.

The objectives of this study were to investigate the associations between workplace risk factors, particularly access to PPE and the risk, severity and duration of COVID-19 among at-risk physicians and nurses from six countries (the UK, Germany, France, Italy, Spain and USA). We leveraged the network of a global healthcare survey firm (Survey Healthcare Globus (SHG)) to access physicians and nurses throughout the UK and Europe in order to gather information about their personal experiences in the COVID-19 pandemic. Historically, large physician panels have been established to aid in healthcare market research. These panels enable market research agencies and consultancies to carry out research on behalf of pharmaceutical and medical device companies so that they may make more informed decisions. In this case, instead of giving their insights to companies to help them make health outcomes decisions, physicians consented to share their own data—demographics, medical, social and lifestyle factors—in order to aid an academic research study of COVID-19.

METHODS

Study design, setting and population

The study design is a population-based case-control study. From the SHG network of 1.5 million physicians and HCWs in the USA or European Union registered as a provider for the purposes of participating in market research studies, we identified at risk physicians and nurses based on medical specialties known to have a high contact frequency with COVID-19 patients (emergency medicine, critical care, subspecialties of internal medicine). Recruitment goals for each country were predetermined, based on the network of SHG, with larger relative size in the USA versus European Union. We used a case-control design because we expected COVID-19 cases to be rarer than controls. COVID-19 was emerging during the study design phase (April 2020); thus, the prevalence of COVID-19 was much lower than at the time of publication (1.8 million cumulative cases in April vs 82 million cumulative cases in December 2020 globally).⁹ We defined cases and controls as participants were being enrolled into the study and found much slower enrolment of cases compared with controls, consistent with our expectation. To ensure comparability between cases and controls, we limited this study to inpatient settings and specific medical specialties who would have been expected to have high frequency of exposure to patients with COVID-19.

The study was open from 17 July 2020 through 25 September 2020. Before completing a questionnaire, participants were screened for self-reported SARS-CoV-2 exposure, specialty, practice setting, COVID-19 symptoms and COVID-19 PCR or antibody results. Participants were unable to enter the questionnaire if they had infrequent exposure (<5% of time) to patients with COVID-19 unless they also had COVID-19 illness or positive test results implying significant exposure, or if they were not from predetermined high-risk fields or practice settings. We selected 5% of time because the prevalence of patients with COVID-19 was low during the study design phase, and to screen for HCWs who have had contact with patients with COVID-19. As a quality control measure, participants were unable to enter the questionnaire if inconsistencies were detected between symptom severity and description. For instance, responses were considered inconsistent if participants rated their symptom severity as 'severe' (respiratory distress (respiratory rate ≥ 30 times/min), low oxygen saturation (SpO₂) <93% at rest) or acute lung injury (partial pressure of oxygen (PaO₂)/ (fraction of inspired oxygen) FiO₂ ≤ 300 mm Hg)), but participants did not select any of these specific symptoms to describe their experience with COVID-19. Seven thousand three hundred forty-four participants were prescreened to enter the study and 4460 were not eligible and were terminated before the questionnaire was administered. Two thousand four hundred and eighty-two did not have close contact or proximity with patients with COVID-19 at work (or not sure), 631 were physicians in fields other than those predetermined as high risk, 559

nurses were not in a high-risk setting (hospital-based), 181 participants did not consent, 57 had inconsistent responses between symptoms and disease severity, and 550 were over quota for negative/asymptomatic controls.

Questionnaires were administered to 2884 exposed HCWs throughout the USA, UK, Germany, France, Italy and Spain. The questionnaire was completed online. It consisted of approximately 100 questions including demographics, medical history, social history, medication and supplements, a food frequency questionnaire, sleep habits, stress and physical activity. SHG offered participants a small honorarium for participation. Questionnaires and informed consent were translated and administered in the primary language for each country (English—USA and UK, Spanish—Spain, French—France, Italian—Italy and German—Germany).

Patient and public involvement

Due to the rapid spread of COVID-19 and the need to disseminate the results of the study as quickly as possible, patients were not involved in the recruitment, design, conduct or interpretation of the study or development of research questions or outcomes measures.

Ascertainment of COVID-19 cases and controls

HCWs were considered to be COVID-19 cases based on their report of COVID-19 diagnosis and symptoms with an affirmative response to the following question: ‘Since exposure, have you personally experienced symptoms consistent with a diagnosis of COVID-19 (fever, coughing, fatigue, loss of taste or smell)?’ Symptoms and symptom severity were recorded in subsequent questions. HCWs were considered to be COVID-19 controls if they if they did not experience symptoms consistent with a diagnosis of COVID-19 (were asymptomatic) and did not report a positive SARS-CoV2 PCR or antibody test. We used both symptoms and positive SARS-CoV2 PCR or antibody test to define cases because many HCWs in Europe would not have had timely access to testing in the earlier phase of the pandemic. Further, testing negative for SARS-CoV2 antibodies does not necessarily indicate that an individual, in fact, did not have COVID-19.

Exposures

Participants reported the amount of time they were in close proximity to patients with COVID-19 by answering the question ‘On a typical shift during the COVID-19 pandemic, how frequently were you in close proximity to patients or others with COVID-19?’ Participants had six options to choose, ranging from <5% of time to >75% of time. Participants reported whether they had been in close contact with a patient with COVID-19 outside the workplace (‘Have you been in close contact with anyone outside of your workplace with a confirmed diagnosis of COVID-19?’). Similarly, participants reported whether they had been in close contact with suspected or confirmed patients with COVID-19 inside the workplace while not wearing PPE (‘Have you been in close contact

with any suspected or confirmed case of COVID-19 inside your workplace while not wearing COVID-recommended PPE?’). For these two questions, participants could answer ‘yes’, ‘no’ or ‘not sure’.

Participants reported the number of shifts per week, number of hours per shift, work hours per week, and whether they had been in a room of a confirmed COVID-19 patient during continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), nebulisation, intubation or cardiopulmonary resuscitation (CPR). Participants were asked to describe their access to PPE (masks, face shields, gowns and gloves) by choosing the following options: ‘non-existent (no access to at least one of the following: masks, face shields, gowns, and gloves)’, ‘poor (little access to masks, face shields, gowns, and gloves)’, ‘basic (access to at least one daily mask, face shield, gown, and gloves)’, ‘good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield)’, ‘excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield)’. A copy of the questionnaire is available as online supplemental file 1.

Statistical analyses

Categorical data were reported as percent frequencies and compared by χ^2 or Fischer exact tests. Mean and SD were employed to display normally distributed continuous variables. Due to the limited number of cases, we pooled data from all six countries in our analyses, except for the analyses on access to PPE and COVID-19-like illnesses. First, we assessed the association of COVID-19 exposures with COVID-19 like illness using multivariable logistic regression models, adjusting for age, gender and country. Second, we examined the association between workplace risk factors and COVID-19 like illness. In addition to age, gender and country, models were further adjusted for access to PPE and close exposure to a COVID-19 case outside the workplace. Third, we evaluated the association between access to PPE and COVID-19 like illness in all six countries and stratified by each country. When we combined data from all six countries, we considered age, gender, country, specialty, provider type, close exposure inside the workplace without PPE and close exposure outside the workplace as covariates. Lastly, the association between COVID-19 risk factors and duration and severity of illness was analysed with multivariable linear regression models controlling for potential confounders such as: age, sex, geographical region, medical history and COVID-19 exposure outside of the workplace. A sensitivity analysis was carried out evaluating the association of COVID-19 risk factors after limiting cases to those who tested positive by antibody or PCR.

RESULTS

The study population consisted according to COVID-19 illness are shown in [table 1](#). The study population

Table 1 Baseline characteristics of physicians, nurses or physician assistants exposed to patients with COVID-19 in the workplace.

	Controls n=2316	Cases n=568	P value
Gender, N (%)			0.63
Female	640 (28%)	154 (27%)	
Male	1656 (72%)	410 (72%)	
Other	1 (0%)	1 (0%)	
Prefer not to say	19 (1%)	3 (1%)	
Age (mean±SD)	48±10	47±10	0.11
Significant, close exposure to COVID-19	100%	100%	.
Experienced symptoms of COVID-19	0 (0%)	514 (90%)	.
Number of days of symptoms	0	11±13	.
Country			<0.001
France	208 (9%)	48 (8%)	
Germany	233 (10%)	46 (8%)	
Italy	359 (16%)	74 (13%)	
Spain	382 (16%)	146 (26%)	
UK	233 (10%)	94 (17%)	
USA	901 (39%)	160 (28%)	
Race/ethnicity			0.46
White	1792 (77%)	426 (75%)	
Any mixed/multiple ethnic background	121 (5%)	41 (7%)	
Asian	271 (12%)	65 (11%)	
African	36 (2%)	12 (2%)	
Other	29 (1%)	7 (1%)	
Prefer not to say	67 (3%)	17 (3%)	
Smoking			0.80
Current smoker	110 (5%)	24 (4%)	
Former smoker	341 (15%)	86 (15%)	
Never smoked	1865 (81%)	458 (81%)	
Medical doctor	2187 (94%)	548 (96%)	0.048
Nurse/nurse practitioner/physician assistant	129 (6%)	20 (4%)	
Physician specialty			0.10
Other	10 (0%)	2 (0%)	
Allergy and immunology	25 (1%)	4 (1%)	
Cardiology	227 (10%)	54 (10%)	
Critical care	230 (10%)	52 (9%)	
Emergency medicine	512 (22%)	91 (16%)	
Endocrinology, diabetes, and metabolism	74 (3%)	24 (4%)	

Continued

Table 1 Continued

	Controls n=2316	Cases n=568	P value
Gastroenterology	77 (3%)	17 (3%)	
Haematology	85 (4%)	27 (5%)	
Infectious disease	82 (4%)	18 (3%)	
Internal medicine	322 (14%)	111 (20%)	
Nephrology	38 (2%)	15 (3%)	
Neurology	82 (4%)	25 (5%)	
Pulmonology	354 (15%)	76 (13%)	
Rheumatology	69 (3%)	32 (6%)	
Nurse/NP/PA practice setting			0.36
Emergency room	22 (17%)	2 (10%)	
Intensive care unit (ICU)	45 (35%)	5 (25%)	
Other hospital-based department	62 (48%)	13 (65%)	
Medical conditions			
Pre-diabetes	38 (1.6%)	16 (2.8%)	0.06
Diabetes	70 (3.0%)	26 (4.6%)	0.06
High cholesterol	320 (13.8%)	76 (13.4%)	0.79
Cancer	326 (14.1%)	78 (13.7%)	0.83
Coronary heart disease	59 (2.5%)	11 (1.9%)	0.4
Heart failure	31 (1.3%)	13 (2.3%)	0.1
Prior lung disease	8 (0.3%)	2 (0.4%)	0.98
Prior lung infection	9 (0.4%)	4 (0.7%)	0.31
Asthma	34 (1.5%)	6 (1.1%)	0.45
Overweight	218 (9.4%)	69 (12.1%)	0.05
Autoimmune disease	307 (13.3%)	81 (14.3%)	0.53
COVID-19 PCR or antibody test			<0.001
No—I did not get a test	695 (30%)	53 (9%)	
No—I did not have access to the test	69 (3%)	32 (6%)	
Yes—I tested negative	1552 (67%)	185 (33%)	
Yes—I tested positive	0 (0%)	298 (52%)	
Test for influenza or other respiratory viruses			<0.001
No—I did not get a test	1876 (81%)	418 (74%)	
No—I did not have access to the test	205 (9%)	50 (9%)	
Yes—I tested negative	225 (10%)	79 (14%)	
Yes—I tested positive	10 (0%)	21 (4%)	

Cases are defined as self-reported COVID-19 like illness or a positive COVID-19 test in the absence of symptoms.
NP, nurse practitioner; PA, physician assistant.

comprised primarily of male physicians with an average age in their late forties (table 1). By study design, all study participants had close exposure to COVID-19 cases, and were similar in terms of sex, age, race/ethnicity, smoking, and medical specialty by cases and controls. COVID-19 cases experienced symptoms with an average duration of 11 days. HCWs were represented from France, Germany, UK, Italy, Spain and USA in ascending order. The study population was primarily composed of self-reported white individuals; report of COVID-19 illness did not differ by race/ethnicity. Physicians were selected for fields that had frequent and close exposure to COVID-19 patients: emergency medicine, critical care, general internal medicine and its subspecialties and neurology. Nurse practitioners, nurses and physicians' assistants were hospital based or worked in the intensive care unit or emergency room. COVID-19 case group was slightly more likely to have pre-diabetes and diabetes, or to be overweight, although these differences were not statistically significant. The majority of the study population received testing for SARS-CoV2 viral infection by PCR or antibody test. Sixty-seven per cent of the asymptomatic control group tested negative while 33% did not have access or did not get a test. Fifty-two per cent of the COVID-19 case group was positive for PCR or antibody test, 33% tested negative and 15% did not have access or did not get a test. Most of the study population was not tested for other respiratory viruses. Twenty-one cases tested positive for influenza or another respiratory virus, nineteen of which also had a positive COVID-19 PCR or antibody test.

The odds of reporting COVID-19 was greater with more frequent contact with patients with COVID-19 in the workplace (P trend <0.0001) (table 2). Close contact

with any suspected or confirmed case of COVID-19 inside the workplace while not wearing COVID-19 recommended PPE was associated with greater odds of reporting COVID-19 illness ($p < 0.0001$). Furthermore, close contact with anyone outside the workplace with a confirmed diagnosis of COVID-19 was associated with greater odds of reporting COVID-19 illness ($p < 0.0001$).

The number of shifts per week but not number of work hours per shift was significantly associated with reporting COVID-19 illness ($p = 0.028$) with 7% greater odds of COVID-19 illness per shift (table 3). Weekly work hours were also associated with increased risk of reporting COVID-19 illness after adjusting for age, gender, country, access to PPE and close exposure to a COVID-19 case outside the workplace. High-risk procedures such as being in a room with a patient during CPAP or BiPAP, nebulisation, intubation or CPR were not associated with reporting COVID-19 illness after adjusting for access to PPE and exposure to COVID-19 cases outside of the work setting.

Access to PPE in exposed frontline HCWs and risk of reporting COVID-19 illness are displayed in figure 1 and online supplemental table 1. In all countries, odds of reporting COVID-19 illness was nearly eightfold greater with non-existent access to PPE, threefold greater with poor access to PPE, twofold greater with basic access to PPE and 1.5-fold greater with good access to PPE, versus those with excellent access (p trend <0.0001) (figure 1; online supplemental table 1). In general, these associations were statistically significant in the USA, UK, Spain and Italy but did not reach statistical significance in Germany and France independently.

Table 2 COVID-19 exposures and ORs of COVID-19 like illness (self-reported COVID-19 like illness or a positive COVID-19 test) in exposed healthcare workers adjusting for age, gender, and country

	OR (95% CI)	P value
Contact with COVID-19 patients in the workplace:		<0.0001*
Not very frequent (5%–10% of my time)	Ref	–
Somewhat frequent (11%–25% of my time)	1.13 (0.84 to 1.52)	0.4
Frequent (26%–50% of my time)	1.40 (1.03 to 1.89)	0.031
Very frequent (51%–75% of my time)	1.69 (1.22 to 2.33)	0.0014
Continuous (greater than 75% of my time)	1.65 (1.19 to 2.28)	0.0026
Close contact with any <i>suspected or confirmed</i> case of COVID-19 <i>inside</i> the workplace while <i>not wearing</i> COVID-recommended PPE		
No	Ref	–
Not sure	1.53 (1.18 to 1.98)	0.0015
Yes	1.65 (1.34 to 2.04)	<0.0001
Close contact with anyone <i>outside</i> the workplace with a confirmed diagnosis of COVID-19		
No	Ref	–
Not sure	0.86 (0.67 to 1.11)	0.26
Yes	1.87 (1.49 to 2.33)	<0.0001

*This value is p trend.

Table 3 Workplace risk factors and ORs of COVID-19 like illness (self-reported COVID-19 like illness or a positive COVID-19 test) in exposed healthcare workers adjusting for age, gender and country and model 2 age, gender, country, access to personal protective equipment (PPE) and close exposure to a COVID-19 case outside the workplace

	Model 1*	P value	Model 2†	P value
Number of shifts per week	1.08 (1.02–1.15)	0.009	1.07 (1.01–1.14)	0.028
Number of work hours per shift	1.00 (0.95–1.04)	0.14	1.01 (0.96–1.05)	0.80
Work hours per week	1.01 (1.00–1.01)	0.015	1.01 (1.00–1.01)	0.018
Been in the room of a patient with <i>confirmed</i> COVID-19 during any of the following:				
CPAP or BiPAP	0.78 (0.64–0.95)	0.012	0.86 (0.70–1.04)	0.125
Nebulisation	0.91 (0.74–1.12)	0.37	0.89 (0.72–1.10)	0.295
Intubation	0.72 (0.58–0.89)	0.003	0.83 (0.67–1.03)	0.086
CPR	0.91 (0.71–1.15)	0.42	0.98 (0.77–1.24)	0.89
None of the above	1.24 (1.02–1.51)	0.032	1.14 (0.94–1.39)	0.19

*Model 1 adjusted for age, gender and country.

†Model 2 adjusted for age, gender, country, access to personal protective equipment (PPE) and close exposure to a COVID-19 case outside the workplace.

BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation.

HCWs were more likely to report greater than 14 days of symptoms ($p=0.004$) and moderate-to-severe symptoms ($p=0.006$) with poor access to PPE relative to excellent access to PPE even after multivariable adjustment including comorbidities (table 4). Reporting symptoms of nausea or vomiting ($p=0.029$), sore throat or headache ($p=0.039$), and fever or chills ($p=0.049$) were significantly associated with less access to PPE. Respiratory symptoms such as shortness of breath or difficulty breathing ($p=0.021$), abnormal chest X-ray, low oxygen saturation, respiratory distress or acute lung injury ($p=0.036$) were also significantly associated with less access to PPE among

HCWs. For analyses on number of days, severity and symptoms of COVID-19, we did not stratify by country due to limited number of cases in each country.

The main study findings were unchanged in a sensitivity analysis limited to cases who tested positive for SARs-CoV-2 by PCR or antibody testing ($n=298$, 11.4%) and this did not change the main study findings (online supplemental tables 2-5). There was a statically significant association between access to PPE and odds of positive COVID-19 test (PCR or antibody) as well (p trend <0.0001 , online supplemental table 4).




Figure 1 Access to personal protective equipment (PPE) and ORs of COVID-19 like illness (self-reported COVID-19 like illness or a positive COVID-19 test) in exposed healthcare workers. The dots represent ORs and the lines represents 95% CIs. Model for all countries ($n=2884$; $n=568$ cases) was adjusted for age, gender, country, specialty, provider type and closer exposure to a COVID-19 case inside the workplace without PPE and close exposure outside of the workplace. Models for each country was adjusted for age, gender, close exposure to a COVID-19 case inside the workplace without PPE and close exposure outside of the workplace. P values represent p for trend. Point estimates and 95% CIs are available in online supplemental table 1.

DISCUSSION

Statement of principal findings

In a large population of exposed physicians and nurses living in six different countries in Europe and the USA, risk of reporting COVID-19 was significantly associated with close contact with COVID-19 cases both inside and outside the workplace, number of work shifts and hours worked per week. Limited access to PPE was associated with a significantly increased risk of reporting COVID-19 across all six countries. Limited access to PPE was associated with symptom duration of greater than 2 weeks and moderate-to-severe symptoms such as nausea or vomiting, fever or chills, difficulty breathing or shortness of breath, abnormal chest X-ray, low oxygen saturations, respiratory distress or acute lung injury.

Importantly, this study shows a strong, consistent relationship between access to PPE and COVID-19 risk in exposed physicians and nurses across multiple countries. Our findings incrementally add to prior studies which examined the associations between PPE and COVID-19 in a single country with sample sizes ranging from 37 to 5442^{10–12} and are in line with several other observational studies that support the importance of PPE in stopping the transmission of COVID-19.^{4 5 13 14} At-risk providers

Table 4 Number of days, severity and type of COVID-19 symptoms in association with access to personal protective equipment (PPE) in exposed healthcare workers

	OR access to PPE good versus excellent	OR access to PPE basic versus excellent	OR access to PPE poor versus excellent	P trend
>14 days of symptoms	1.26 (0.62–2.55)	1.76 (0.86–3.61)	2.39 (1.10–5.22)	0.0044
Moderate to severe symptoms	1.70 (0.90–3.20)	1.63 (0.83–3.19)	3.51 (1.70–7.26)	0.0058
Specific COVID-19 symptoms:				
Fatigue and muscle aches	1.53 (0.79–2.93)	2.07 (1.00–4.30)	0.97 (0.46–2.08)	0.86
Loss of taste or smell	1.17 (0.66–2.09)	1.74 (0.95–3.18)	1.31 (0.67–2.58)	0.46
Cough	1.46 (0.85–2.51)	1.59 (0.90–2.81)	1.48 (0.78–2.79)	0.36
Diarrhoea	1.88 (0.94–3.73)	2.04 (1.01–4.12)	1.79 (0.82–3.89)	0.28
Nausea or vomiting	1.18 (0.53–2.64)	2.53 (1.14–5.59)	2.10 (0.87–5.07)	0.029
Sore throat or headache	2.40 (1.37–4.18)	2.92 (1.62–5.27)	2.15 (1.11–4.14)	0.039
Fever or chills	1.47 (0.85–2.56)	1.49 (0.83–2.65)	2.25 (1.16–4.39)	0.049
Shortness of breath or difficulty breathing	1.10 (0.60–2.03)	1.46 (0.78–2.76)	2.45 (1.22–4.93)	0.021
Respiratory symptoms: abnormal chest X-ray, low oxygen saturation (SpO ₂) <93% at rest, respiratory distress, respiratory rate ≥30 times/min, or acute lung injury	1.48 (0.43–5.09)	1.74 (0.48–6.30)	3.33 (0.93–11.86)	0.036

*Adjusted for age, gender, country, diabetes, pre-diabetes, coronary artery disease, overweight, asthma and high-risk exposure to an individual with COVID-19 outside of the workplace (n=568 total).

†Poor access to PPE was described as ‘little access to masks, face shields, gowns, and gloves’. Basic access was described as ‘access to at least one daily mask, face shield, gown, and gloves’. Good access to PPE was described as ‘I had access to a change of mask, gown, and gloves if soiled as well as a face shield’. Excellent access to PPE was described as ‘I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield’.

who had no access to either a mask, face shield, gown or gloves were eight times more likely to report COVID-19. Risk decreased with some access to more than one of those items and decreased further with daily change of mask, gown and gloves and access to a face shield. Risk was lowest for those providers that could change their mask gown and gloves every time that they entered a new patient room. Risk of COVID-19 may be lower for HCWs with excellent access to PPE, given that PPE can provide a physical protection which can block the spread of respiratory droplets from infected individuals.³ PPE, such as surgical masks, can also reduce virus shedding into the environment.¹⁵

Notably, to the best of our knowledge, this is the largest study thus far to find that greater access to PPE not only reduced the risk of contracting COVID-19, but was associated with reduced severity of the disease in frontline HCWs. Those HCW who reported limited access to masks, gowns, gloves and face shields had a nearly 2.5-fold higher odds of COVID-19 symptoms lasting for more than 14 days and 3.5-fold higher odds of reporting moderate-to-severe symptoms versus those with fresh PPE for each patient encounter. It is possible that this observation is due to a reduced SARS-CoV-2 inoculum as access to PPE was greater, potentially resulting in reduced disease severity. Previously, scientists have hypothesised that universal mask wearing reduces the dose of the virus for the mask-wearer, resulting in milder disease course or asymptomatic infection. Depending on the type of mask, they filter out most but not all viral particles.¹⁶ Several

studies have suggested that viral inoculum of SARS-CoV-2 could be associated with disease severity.^{17–19} Trials in humans to test this notion would be unethical, but animal studies suggest a dose–response relationship.²⁰ The data presented in this study are the largest to date to support this theory.

In this study, we confirmed some obvious workplace risk factors for COVID-19 illness but not others. Reported increased frequency of exposure to patients with COVID-19 in the workplace was associated with higher risk of COVID-19 illness. Magnitude of risk was similar in those with at least very frequent exposure continuously at work as those who had episodic exposure to patients with COVID-19 without proper PPE. Interestingly, the number of shifts worked per week increased risk while the length of the shift did not. Perhaps this could be due to vulnerabilities when donning and doffing PPE in changing or transitional areas in the hospital. Alternatively, there could be risks in transportation to and from home to medical facilities for work. Paradoxically, in a basic model adjusting only for age, gender and country, high-risk procedures such as intubation or CPAP seemed to be associated with lower risk of COVID-19. However, after further adjustment for access to PPE and risk factors outside of the workplace, these associations became non-significant, suggesting that those providers who performed high-risk procedures may have had better access to PPE overall or at least during the high-risk procedures.

Strengths and limitations of study

The study has several strengths, such as large sample size, inclusion of HCWs from multiple countries, and careful adjustment of potential confounders. Our study is also unique in that we were able to capture the period when many countries faced shortages of PPEs. At the time, healthcare system was ill prepared to meet the high PPE demands due to lack of inventories,²¹ leading to a gradient of access to PPE among HCWs.

This study has limitations that must be noted. Case-control studies have various limitations including recall bias regarding exposures. Additional factors that may be associated with COVID-19 illness could not be assessed such as local prevalence of COVID-19 and hospital infection control practices, including patient screening and testing practices. Like other observational studies, results herein represent statistical associations and cannot prove causality. Since randomised trials of PPE and COVID-19 among HCWs may not be ethical, data from prospective cohort studies should ideally be used to replicate our findings. We may have not included HCWs who may be considered high risk.²² However, our study focused on inpatient settings to have comparable cases and controls, and data on medical specialties at high risk of COVID-19 infection were not available at the time of study design. Furthermore, this study relied on participants' self-report of diagnosis, symptoms and test results as opposed to chart review. To restrict the study population to exposed HCWs, we used >5% of time with patients with COVID-19. However, this cut-off may be considered arbitrary and there is a possibility that HCWs may not be able to recall the time they had contact with patients with COVID-19 in the workplace. One study in medical students in UK in the setting of COVID-19 pandemic found that their self-reported level of PPE was not consistent with PPE supply.²³ However, the consistent associations between access to PPE and COVID-19 across multiple countries lends credibility to our results. Future studies should validate self-reported level of PPE and PPE supply in HCWs. Next, we used ORs to estimate the associations between workplace risk factors and COVID-19. However, given how common COVID-19 is as of December 2020, our estimates based on ORs may overestimate the associations. Lastly, our study population mainly comprised middle-aged male physicians. Thus, our findings may not be generalisable to community settings or other groups of individuals, highlighting the need to build more evidence on PPE and COVID-19 in this area.

In conclusion, this study supports that inadequate access to PPE is a strong risk factor for preventing COVID-19 illness in front line workers, further underscoring the need for appropriate PPE. Mask, glove and gown changes for every patient encounter as well as a face shield was associated with the lowest risk for reporting symptoms consistent with COVID-19. Importantly, excellent access to PPE was also associated with shorter and less severe illness, supporting the idea that even when PPE fails, it may reduce viral inoculation.

Author affiliations

¹Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA

²Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

³Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA

⁴Harvard Medical School, Boston, MA, USA

⁵Envision Health Partners, Stamford, CT, USA

⁶Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

⁷Medicine, Stamford Hospital, Stamford, CT, USA

⁸Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA

Acknowledgements The authors thank all healthcare professionals involved in this study. They also thank John Turner and the team from Survey Healthcare Globus for their work and perseverance on this project.

Contributors SBS conceived the study. HK, SH, CF, MR and CR contributed to study design. CF and MR contributed to recruitment of health care professionals and data collection. HK, SC and SBS analysed the data. HK, SH, CF, MR, NS, SC and CR contributed to data interpretation. SBS drafted the manuscript and was involved in all aspects of the study from study design to interpretation. HK and SBS are the guarantors. All authors approved the final version of the manuscript.

Funding This work was funded by Survey Healthcare Globus. The funder was not involved in the analysis, interpretation of data, writing of the report, or decision to submit the article for publication. SC and NS received funding from the National Institutes of Health (U54-CA260591). HK and CMR are supported by grants from the National Heart, Lung, and Blood Institute (R21 HL143089; R56 HL153178) outside of the submitted work.

Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the WIRB IRB through Stamford Hospital, a teaching affiliate of Columbia College of Physicians and Surgeons. Informed consent was obtained electronically before the questionnaire was administered. The consent form contained language describing the nature of the research study and the subject's ability to refuse to participate without any loss of participation in other surveys. All of the risks (and benefits) associated with participation were delineated in the consent form.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- 1 Nguyen LH, Drew DA, Graham MS, *et al*. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* 2020;5:e475–83.

- 2 Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. *JAMA* 2020;323:1439.
- 3 Lerner AM, Folkers GK, Fauci AS. Preventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions. *JAMA* 1935;2020:324.
- 4 Chu DK, Akl EA, Duda S, *et al*. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020;395:1973–87.
- 5 Wang X, Ferro EG, Zhou G, *et al*. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. *JAMA* 2020;324:703.
- 6 Nagesh S, Chakraborty S. Saving the frontline health workforce amidst the COVID-19 crisis: challenges and recommendations. *J Glob Health* 2020;10:010345.
- 7 Verbeek JH, Rajamaki B, Ijaz S, *et al*. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. *Cochrane Database Syst Rev* 2020;4:CD011621.
- 8 Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, *et al*. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial. *Ann Intern Med* 2020. doi:10.7326/M20-6817. [Epub ahead of print: 18 Nov 2020].
- 9 Worldometer. Coronavirus graphs: worldwide cases and deaths. Available: <https://www.worldometers.info/coronavirus/worldwide-graphs/> [Accessed 27 Dec 2020].
- 10 Heinzerling A, Stuckey MJ, Scheuer T, *et al*. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:472–6.
- 11 Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. *J Hosp Infect* 2020;105:104–5.
- 12 Wang Q, Huang X, Bai Y. Epidemiological characteristics of COVID-19 in medical staff members of neurosurgery departments in Hubei Province: a multicentre descriptive study. *medRxiv*2020:2020.04.20.20064899.
- 13 Wang Y, Tian H, Zhang L, *et al*. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health* 2020;5.
- 14 Chou R, Dana T, Jungbauer R, *et al*. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings : A Living Rapid Review. *Ann Intern Med* 2020;173:542–55.
- 15 Leung NHL, Chu DKW, Shiu EYC, *et al*. Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nat Med* 2020;26:676–80.
- 16 Gandhi M, Beyrer C, Goosby E. Masks do more than protect others during COVID-19: reducing the inoculum of SARS-CoV-2 to protect the wearer. *J Gen Intern Med* 2020;35:3063–6.
- 17 Gandhi M, Rutherford GW. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine. *N Engl J Med Overseas Ed* 2020;383:e101.
- 18 Bielecki M, Züst R, Siegrist D, *et al*. Social distancing alters the clinical course of COVID-19 in young adults: a comparative cohort study. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa889. [Epub ahead of print: 29 Jun 2020].
- 19 Guallar MP, Meiriño R, Donat-Vargas C, *et al*. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. *Int J Infect Dis* 2020;97:290–2.
- 20 Imai M, Iwatsuki-Horimoto K, Hatta M, *et al*. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc Natl Acad Sci U S A* 2020;117:16587–95.
- 21 Cohen J, Rodgers YvanderM. Contributing factors to personal protective equipment shortages during the COVID-19 pandemic. *Prev Med* 2020;141:106263.
- 22 Bandyopadhyay S, Baticulon RE, Kadhum M, *et al*. Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review. *BMJ Glob Health* 2020;5:e003097.
- 23 Norton EJ, Georgiou I, Fung A, *et al*. Personal protective equipment and infection prevention and control: a national survey of UK medical students and interim Foundation doctors during the COVID-19 pandemic. *J Public Health* 2020. doi:10.1093/pubmed/ fdaa187. [Epub ahead of print: 23 Oct 2020].

Supplemental Table 1. Access to personal protective equipment (PPE) and odds ratios of Covid-19 like illness in exposed healthcare workers

	OR (95% CI)	P-value	P-trend
Access to PPE All Countries combined* (N=2884 total; 568 cases (20%)):			<0.0001
Nonexistent (no access to at least one of the following: masks, face shields, gowns, and gloves) (n=17; 9 cases)	7.98 (2.86-22.31)	<0.0001	
Poor (little access to masks, face shields, gowns, and gloves) (n=288; 94 cases)	2.72 (1.91-3.87)	<0.0001	
Basic (access to at least one daily mask, face shield, gown, and gloves) (n=728; 162 cases)	1.86 (1.39-2.49)	<0.0001	
Good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield) (n=1,141; 210 cases)	1.50 (1.14-1.97)	0.004	
Excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield) (n=710; 93 cases)	Ref	--	
USA** (N=1061 total; 160 cases (15%))			0.0002
Nonexistent (n=5; 3 cases)	11.1 (1.71-72.3)	0.012	
Poor (n=70; 16 cases)	2.23 (1.10-4.49)	0.042	
Basic (n=298; 59 cases)	2.05 (1.25-3.37)	0.005	
Good (n=446; 54 cases)	1.21 (0.73-1.99)	0.45	
Excellent (n=242; 28 cases)	Ref	--	
UK** (N=327 total; 94 cases (29%))			0.0003
Nonexistent (n=2; 2 cases)	--	--	
Poor (n=18; 10 cases)	5.86 (1.93-17.8)	0.002	
Basic (n=62; 21 cases)	2.22 (1.05-4.67)	0.021	
Good (n=140; 41 cases)	1.69 (0.91-3.145)	0.100	
Excellent (n=105; 20 cases)	Ref	--	
Spain** (N=528 total; 146 cases (28%))			0.0002
Nonexistent (n=3; 2 cases)	22.9 (1.74-301)	0.017	
Poor (n=109; 42 cases)	3.49 (1.53-7.93)	0.003	
Basic (n=152; 47 cases)	2.56 (1.15-5.69)	0.021	
Good (n=197; 46 cases)	1.82 (0.82-4.04)	0.131	
Excellent (n=67; 9 cases)	Ref	--	
Italy** (N=433 total; 74 cases (17%))			0.015
Nonexistent (n=1; 1 case)	--	--	
Poor (n=46; 13 cases)	3.12 (1.36-7.15)	0.007	
Basic (n=82; 12 cases)	1.39 (0.63-3.07)	0.42	
Good (n=138; 30 cases)	2.32 (1.22-4.44)	0.010	
Excellent (n=165; 18 cases)	Ref	--	
Germany** (N=279 total; 46 (16%))			0.34
Nonexistent (n=1; 0 case)	--	--	
Poor (n=21; 6 cases)	2.80 (0.84-9.39)	0.106	
Basic (n=82; 12 cases)	1.08 (0.41-2.84)	0.95	
Good (n=111; 19 cases)	1.41 (0.58-3.43)	0.44	

Excellent (n=64; 9 cases)	Ref	--	
France** (N=256 total; 48 cases (19%))			0.19
Nonexistent (n=5; 1 case)	1.81 (0.17-19.22)	0.61	
Poor (n=24; 7 cases)	2.20 (0.69-7.03)	0.180	
Basic (n=51; 11 cases)	1.53 (0.56-4.19)	0.95	
Good (n=109; 20 cases)	1.36 (0.56-3.30)	0.49	
Excellent (n=67; 9 cases)	Ref	--	

* adjusted for age, gender, country, specialty, provider type, close exposure inside the workplace without PPE and close exposure outside of the workplace (N=568 cases and N=2316 controls).

** adjusted for age, gender, close exposure inside the workplace without PPE and close exposure outside of the workplace

We did not compare access to PPE Nonexistent vs Excellent due to limited number of cases (9 cases).

Supplementary Table 2. Covid-19 exposures and odds ratios of Covid-19 positive test (PCR or antibody) in exposed healthcare workers adjusting for age, gender, and country (N=2614).

	OR (95% CI)	P-value
Contact with Covid-19 patients in the workplace:		
Not very frequent (5-10% of my time)	Ref	--
Somewhat frequent (11-25% of my time)	1.13 (0.74-1.72)	0.58
Frequent (26-50% of my time)	1.51 (0.99-2.31)	0.056
Very frequent (51-75% of my time)	1.92 (1.24-2.97)	0.0036
Continuous (greater than 75% of my time)	1.92 (1.24-2.97)	0.0033
Close contact with any <i>suspected or confirmed</i> case of Covid-19 <i>inside</i> the workplace while <i>not wearing</i> Covid-recommended PPE		
	No Ref	--
	Not sure 1.42 (1.02-2.00)	0.041
	Yes 1.47 (1.12-1.94)	0.00064
Close contact with anyone <i>outside</i> the workplace with a confirmed diagnosis of Covid-19		
	No Ref	--
	Not sure 0.82 (0.59-1.15)	0.25
	Yes 1.73 (1.29-2.31)	0.0002

Supplementary Table 3. Workplace risk factors and odds ratios of positive Covid-19 test (PCR or antibody) in exposed healthcare workers adjusting for age, gender, and country and Model 2 age, gender, country, access to personal protective equipment (PPE) and close exposure to a Covid-19 case outside the workplace (N=2614).

	Model 1*	<i>p</i> -value	Model 2**	<i>p</i> -value
Number of shifts per week	1.11 (1.02-1.21)	0.012	1.10 (1.01-1.20)	0.022
Number of work hours per shift	0.98 (0.92-1.04)	0.53	0.99 (0.93-1.06)	0.80
Work hours per week	1.01 (1.00-1.02)	0.028	1.01 (1.00-1.02)	0.025
Been in the room of a <i>confirmed</i> Covid-19 patient during any of the following:				
CPAP or BiPAP	0.89 (0.69-1.15)	0.37	0.92 (0.71-1.19)	0.52
Nebulization	1.02 (0.78-1.32)	0.90	1.01 (0.77-1.32)	0.67
Intubation	0.74 (0.56-0.98)	0.038	0.77 (0.58-1.02)	0.069
CPR	1.08 (0.80-1.46)	0.62	1.07 (0.79-1.46)	0.66
None of the above	1.12 (0.87-1.46)	0.37	1.09 (0.84-1.41)	0.53

* Model 1 adjusted for age, gender, and country

** Model 2 adjusted for age, gender, country, access to personal protective equipment (PPE) and close exposure to a Covid-19 case outside the workplace.

Abbreviations: BiPAP, Bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation

Abbreviations: BiPAP, Bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation

Supplemental Table 4. Access to personal protective equipment (PPE) and odds ratios of positive Covid-19 test (PCR or antibody) in exposed healthcare workers

	OR (95% CI)	P-value	P-trend
Access to PPE All Countries combined* (N=2614 total; 298 cases (11.4%)):			<0.0001
Nonexistent (no access to at least one of the following: masks, face shields, gowns, and gloves) (n=14; 3 cases)	5.37 (1.29-22.4)	0.021	
Poor (little access to masks, face shields, gowns, and gloves) (n=238; 50 cases)	2.46 (1.57-3.85)	<0.0001	
Basic (access to at least one daily mask, face shield, gown, and gloves) (n=650; 78 cases)	1.60 (1.09-2.35)	0.017	
Good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield) (n=1,027; 114 cases)	1.46 (1.03-2.08)	0.035	
Excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield) (n=657; 53 cases)	Ref	--	

*adjusted for age, gender, country, close exposure inside the workplace without PPE and close exposure outside of the workplace (N=298 cases and N=2316 controls).

Supplementary Table 5. Number of days, severity and type of Covid-19 symptoms (in those that tested positive by PCR or antibodies) in association with access to personal protective equipment in exposed Healthcare workers (N=298)^{1,2*}

	OR access to PPE Good vs Excellent	OR access to PPE Basic vs Excellent	OR access to PPE Poor vs Excellent	P-value trend
>14 days of symptoms	2.01 (0.74-5.49)	2.82 (0.99-8.07)	5.65 (1.84-17.4)	0.0008
Moderate to severe symptoms	2.93 (1.24-6.99)	2.52 (0.98-6.47)	4.95 (1.76-13.9)	0.038
Specific Covid-19 symptoms:				
Fatigue and Muscle Aches	0.77 (0.21-2.73)	1.20 (0.29-4.93)	0.73 (0.16-3.13)	0.65
Loss of taste or smell	1.16 (0.46-2.89)	3.32 (1.21-9.07)	2.46 (0.83-7.35)	0.028
Cough	1.55 (0.69-3.50)	1.70 (0.70-4.11)	1.69 (0.65-4.44)	0.54
Diarrhea	1.62 (0.65-4.04)	1.77 (0.66-4.70)	1.01 (0.34-3.04)	0.17
Nausea or Vomiting	1.16 (0.36-3.72)	4.35 (1.24-15.2)	3.41 (0.87-13.4)	0.056
Sore throat or Headache	2.19 (0.98-4.91)	3.76 (1.50-9.39)	2.55 (0.96-46.74)	0.016
Fever or Chills	2.11 (0.90-4.92)	1.88 (0.76-4.66)	2.41 (0.86-6.74)	0.216
Shortness of breath or difficulty breathing	1.36 (0.56-3.31)	1.65 (0.62-4.41)	2.91 (1.00-8.44)	0.18
Respiratory symptoms: Abnormal Chest X-ray, Low oxygen saturation, SpO2 <93% at rest, Respiratory distress, Respiratory rate ≥30 times/min, or acute lung injury	2.78 (0.59-13.1)	3.73 (0.72-19.3)	7.29 (1.37-38.7)	0.058

¹ *adjusted for age, gender, country, diabetes, pre-diabetes, overweight and high-risk exposure to an individual with Covid-19 outside of the workplace.

² Poor access to PPE was described as “little access to masks, face shields, gowns, and gloves.” Basic access was described as “access to at least one daily mask, face shield, gown, and gloves.” Good access to PPE was described as “I had access to a change of mask, gown, and gloves if soiled as well as a face shield.” Excellent access to PPE was described as “I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield.”

Supplemental Table 1. Access to personal protective equipment (PPE) and odds ratios of Covid-19 like illness in exposed healthcare workers

	OR (95% CI)	P-value	P-trend
Access to PPE All Countries combined* (N=2884 total; 568 cases (20%)):			<0.0001
Nonexistent (no access to at least one of the following: masks, face shields, gowns, and gloves) (n=17; 9 cases)	7.98 (2.86-22.31)	<0.0001	
Poor (little access to masks, face shields, gowns, and gloves) (n=288; 94 cases)	2.72 (1.91-3.87)	<0.0001	
Basic (access to at least one daily mask, face shield, gown, and gloves) (n=728; 162 cases)	1.86 (1.39-2.49)	<0.0001	
Good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield) (n=1,141; 210 cases)	1.50 (1.14-1.97)	0.004	
Excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield) (n=710; 93 cases)	Ref	--	
USA** (N=1061 total; 160 cases (15%))			0.0002
Nonexistent (n=5; 3 cases)	11.1 (1.71-72.3)	0.012	
Poor (n=70; 16 cases)	2.23 (1.10-4.49)	0.042	
Basic (n=298; 59 cases)	2.05 (1.25-3.37)	0.005	
Good (n=446; 54 cases)	1.21 (0.73-1.99)	0.45	
Excellent (n=242; 28 cases)	Ref	--	
UK** (N=327 total; 94 cases (29%))			0.0003
Nonexistent (n=2; 2 cases)	--	--	
Poor (n=18; 10 cases)	5.86 (1.93-17.8)	0.002	
Basic (n=62; 21 cases)	2.22 (1.05-4.67)	0.021	
Good (n=140; 41 cases)	1.69 (0.91-3.145)	0.100	
Excellent (n=105; 20 cases)	Ref	--	
Spain** (N=528 total; 146 cases (28%))			0.0002
Nonexistent (n=3; 2 cases)	22.9 (1.74-301)	0.017	
Poor (n=109; 42 cases)	3.49 (1.53-7.93)	0.003	
Basic (n=152; 47 cases)	2.56 (1.15-5.69)	0.021	
Good (n=197; 46 cases)	1.82 (0.82-4.04)	0.131	
Excellent (n=67; 9 cases)	Ref	--	
Italy** (N=433 total; 74 cases (17%))			0.015
Nonexistent (n=1; 1 case)	--	--	
Poor (n=46; 13 cases)	3.12 (1.36-7.15)	0.007	
Basic (n=82; 12 cases)	1.39 (0.63-3.07)	0.42	
Good (n=138; 30 cases)	2.32 (1.22-4.44)	0.010	
Excellent (n=165; 18 cases)	Ref	--	
Germany** (N=279 total; 46 (16%))			0.34
Nonexistent (n=1; 0 case)	--	--	
Poor (n=21; 6 cases)	2.80 (0.84-9.39)	0.106	
Basic (n=82; 12 cases)	1.08 (0.41-2.84)	0.95	
Good (n=111; 19 cases)	1.41 (0.58-3.43)	0.44	

Excellent (n=64; 9 cases)	Ref	--	
France** (N=256 total; 48 cases (19%))			0.19
Nonexistent (n=5; 1 case)	1.81 (0.17-19.22)	0.61	
Poor (n=24; 7 cases)	2.20 (0.69-7.03)	0.180	
Basic (n=51; 11 cases)	1.53 (0.56-4.19)	0.95	
Good (n=109; 20 cases)	1.36 (0.56-3.30)	0.49	
Excellent (n=67; 9 cases)	Ref	--	

* adjusted for age, gender, country, specialty, provider type, close exposure inside the workplace without PPE and close exposure outside of the workplace (N=568 cases and N=2316 controls).

** adjusted for age, gender, close exposure inside the workplace without PPE and close exposure outside of the workplace

We did not compare access to PPE Nonexistent vs Excellent due to limited number of cases (9 cases).

Supplementary Table 2. Covid-19 exposures and odds ratios of Covid-19 positive test (PCR or antibody) in exposed healthcare workers adjusting for age, gender, and country (N=2614).

	OR (95% CI)	P-value
Contact with Covid-19 patients in the workplace:		
Not very frequent (5-10% of my time)	Ref	--
Somewhat frequent (11-25% of my time)	1.13 (0.74-1.72)	0.58
Frequent (26-50% of my time)	1.51 (0.99-2.31)	0.056
Very frequent (51-75% of my time)	1.92 (1.24-2.97)	0.0036
Continuous (greater than 75% of my time)	1.92 (1.24-2.97)	0.0033
Close contact with any <i>suspected or confirmed</i> case of Covid-19 <i>inside</i> the workplace while <i>not wearing</i> Covid-recommended PPE		
	No Ref	--
	Not sure 1.42 (1.02-2.00)	0.041
	Yes 1.47 (1.12-1.94)	0.00064
Close contact with anyone <i>outside</i> the workplace with a confirmed diagnosis of Covid-19		
	No Ref	--
	Not sure 0.82 (0.59-1.15)	0.25
	Yes 1.73 (1.29-2.31)	0.0002

Supplementary Table 3. Workplace risk factors and odds ratios of positive Covid-19 test (PCR or antibody) in exposed healthcare workers adjusting for age, gender, and country and Model 2 age, gender, country, access to personal protective equipment (PPE) and close exposure to a Covid-19 case outside the workplace (N=2614).

	Model 1*	<i>p</i> -value	Model 2**	<i>p</i> -value
Number of shifts per week	1.11 (1.02-1.21)	0.012	1.10 (1.01-1.20)	0.022
Number of work hours per shift	0.98 (0.92-1.04)	0.53	0.99 (0.93-1.06)	0.80
Work hours per week	1.01 (1.00-1.02)	0.028	1.01 (1.00-1.02)	0.025
Been in the room of a <i>confirmed</i> Covid-19 patient during any of the following:				
CPAP or BiPAP	0.89 (0.69-1.15)	0.37	0.92 (0.71-1.19)	0.52
Nebulization	1.02 (0.78-1.32)	0.90	1.01 (0.77-1.32)	0.67
Intubation	0.74 (0.56-0.98)	0.038	0.77 (0.58-1.02)	0.069
CPR	1.08 (0.80-1.46)	0.62	1.07 (0.79-1.46)	0.66
None of the above	1.12 (0.87-1.46)	0.37	1.09 (0.84-1.41)	0.53

* Model 1 adjusted for age, gender, and country

** Model 2 adjusted for age, gender, country, access to personal protective equipment (PPE) and close exposure to a Covid-19 case outside the workplace.

Abbreviations: BiPAP, Bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation

Abbreviations: BiPAP, Bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation

Supplemental Table 4. Access to personal protective equipment (PPE) and odds ratios of positive Covid-19 test (PCR or antibody) in exposed healthcare workers

	OR (95% CI)	P-value	P-trend
Access to PPE All Countries combined* (N=2614 total; 298 cases (11.4%)):			<0.0001
Nonexistent (no access to at least one of the following: masks, face shields, gowns, and gloves) (n=14; 3 cases)	5.37 (1.29-22.4)	0.021	
Poor (little access to masks, face shields, gowns, and gloves) (n=238; 50 cases)	2.46 (1.57-3.85)	<0.0001	
Basic (access to at least one daily mask, face shield, gown, and gloves) (n=650; 78 cases)	1.60 (1.09-2.35)	0.017	
Good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield) (n=1,027; 114 cases)	1.46 (1.03-2.08)	0.035	
Excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield) (n=657; 53 cases)	Ref	--	

*adjusted for age, gender, country, close exposure inside the workplace without PPE and close exposure outside of the workplace (N=298 cases and N=2316 controls).

Supplementary Table 5. Number of days, severity and type of Covid-19 symptoms (in those that tested positive by PCR or antibodies) in association with access to personal protective equipment in exposed Healthcare workers (N=298)^{1,2*}

	OR access to PPE Good vs Excellent	OR access to PPE Basic vs Excellent	OR access to PPE Poor vs Excellent	P-value trend
>14 days of symptoms	2.01 (0.74-5.49)	2.82 (0.99-8.07)	5.65 (1.84-17.4)	0.0008
Moderate to severe symptoms	2.93 (1.24-6.99)	2.52 (0.98-6.47)	4.95 (1.76-13.9)	0.038
Specific Covid-19 symptoms:				
Fatigue and Muscle Aches	0.77 (0.21-2.73)	1.20 (0.29-4.93)	0.73 (0.16-3.13)	0.65
Loss of taste or smell	1.16 (0.46-2.89)	3.32 (1.21-9.07)	2.46 (0.83-7.35)	0.028
Cough	1.55 (0.69-3.50)	1.70 (0.70-4.11)	1.69 (0.65-4.44)	0.54
Diarrhea	1.62 (0.65-4.04)	1.77 (0.66-4.70)	1.01 (0.34-3.04)	0.17
Nausea or Vomiting	1.16 (0.36-3.72)	4.35 (1.24-15.2)	3.41 (0.87-13.4)	0.056
Sore throat or Headache	2.19 (0.98-4.91)	3.76 (1.50-9.39)	2.55 (0.96-46.74)	0.016
Fever or Chills	2.11 (0.90-4.92)	1.88 (0.76-4.66)	2.41 (0.86-6.74)	0.216
Shortness of breath or difficulty breathing	1.36 (0.56-3.31)	1.65 (0.62-4.41)	2.91 (1.00-8.44)	0.18
Respiratory symptoms: Abnormal Chest X-ray, Low oxygen saturation, SpO2 <93% at rest, Respiratory distress, Respiratory rate ≥30 times/min, or acute lung injury	2.78 (0.59-13.1)	3.73 (0.72-19.3)	7.29 (1.37-38.7)	0.058

¹ *adjusted for age, gender, country, diabetes, pre-diabetes, overweight and high-risk exposure to an individual with Covid-19 outside of the workplace.

² Poor access to PPE was described as “little access to masks, face shields, gowns, and gloves.” Basic access was described as “access to at least one daily mask, face shield, gown, and gloves.” Good access to PPE was described as “I had access to a change of mask, gown, and gloves if soiled as well as a face shield.” Excellent access to PPE was described as “I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield.”

S0. COUNTRY SELECTION. BEHIND THE SCENES.

1. UK
2. FRANCE
3. GERMANY
4. SPAIN
5. ITALY
6. USA

Intro.

Please read the following and select your response at the bottom of the page.

Understanding nutritional and lifestyle related risk factors associated with Covid-19 susceptibility and disease course in physicians and nurses may help to develop supportive strategies for protecting them and others in the future. To create a resource to study risk factors for Covid-19, a group of academic physicians and scientists from Columbia and Harvard Medical Schools and Johns Hopkins School of Public Health have developed this survey with an emphasis on nutritional and lifestyle factors. This survey is being conducted by Envision Health Partners, an independent market research agency. Taking this opportunity to have your voice heard would greatly help us further our research, and your participation would be hugely appreciated.

This survey will take approximately 10 minutes to complete.

Your participation in this survey is voluntary. If you do not wish to complete this survey, you do not need to do so. In no way will you be penalized if you do not wish to participate in the survey.

Your information will be kept confidential and will not be associated with you specifically if you choose to participate in this survey. As part of this survey, we will collect demographic information which will be anonymised. All survey data will be reported in the aggregate only.

If you have questions about your rights as a research participant, or concerns or complaints about the research, please contact **Christine LaFiura** at **Envision Health Partners** by email Clafiura@envisionhealthllc.com

[For US (S0=6)Show]: The research will comply with the Insights Association's Legal & Ethical Guidelines.

[For EU (non-UK (S0=2-5) show): The research will comply with GDPR Data protection law, as well as the Insights Association and European Pharmaceutical Market Research Association (EphMRA) Legal & Ethical Guidelines.

[For UK (S0=1) show]: The research will comply with UK Data Protection law and with the British Healthcare Business Intelligence Association's Legal & Ethical Guidelines.

By signing below/clicking on the box below:

S0A.

I consent to **Envision Health Partners** collecting and using de-identified information about me that I voluntarily provide for the purposes of research.

1. Yes
2. No

S0B.

I have read, understand and agree to the terms described above.

1. Yes
2. No

[Work]

[ALL CONTINUING RESPONDENTS]

S1. Please select what describes you best. *Select one.*

1. Nurse/Nurse Practitioner/Physician Assistant
2. Physician
3. All Other

[ALL CONTINUING PHYSICIANS (S1=2)]

S2. Which best describes your focus? *Select one.* **[ALPHABETIZE 1-12]**

1. Emergency Medicine
2. Critical Care
3. Internal Medicine
4. Pulmonology
5. Cardiology
6. Rheumatology
7. Endocrinology, Diabetes, and Metabolism
8. Gastroenterology
9. Allergy and Immunology
10. Hematology
11. Family Medicine
12. Pediatrics
13. Other (specify: _____)

[ALL CONTINUING NURSES/NPs/PAs (S1=1)]

S2X. Which best describes your primary practice setting? *Select one.*

1. Private practice / doctor's office
2. Community clinic
3. Comprehensive cancer centre
4. Emergency room
5. Intensive Care Unit (ICU)
6. Other hospital-based department
7. Other, specify: _____

[BANK S3 AND S4 ON SAME SCREEN]**[ALL CONTINUING RESPONDENTS, S1=1-2]**

S3. Prior to the Covid-19 pandemic, how long was your typical work shift in hours?

[Drop Down Menu: Range 1-24]

[ALL CONTINUING RESPONDENTS, S1=1-2]

S4. Prior to the Covid-19 pandemic, how many shifts did you work each week?

[Drop Down Menu Range 1-10]

[Covid-19 related questions]

Now, thinking about the current Covid-19 pandemic...

[ALL CONTINUING RESPONDENTS, S1=1-2]

S5. To your knowledge, have you had significant close contact with Covid-19 (SARS-CoV2) patients in your workplace? *Select one.*

(Face-to-face within 6 feet for ≥ 10 minutes)

1. Yes
2. No
3. Not sure

[BANK S6b AND S7 ON SAME SCREEN]**[ALL CONTINUING RESPONDENTS, S5=1]**

S6b. On a typical shift during the Covid-19 pandemic, how frequently were you in close proximity to patients or others with Covid-19? *Select one.*

(Face-to-face within 6 feet for ≥ 10 minutes)

1. Infrequent (<5% of my time)
2. Not very frequent (5-10% of my time)
3. Somewhat frequent (11-25% of my time)
4. Frequent (26-50% of my time)
5. Very frequent (51-75% of my time)
6. Continuous (greater than 75% of my time)

[ALL CONTINUING RESPONDENTS, S5=1]

S7. Since exposure, have you personally experienced symptoms consistent with a diagnosis of Covid-19 (fever, coughing, fatigue, loss of taste or smell)?

Select one.

1. Yes
2. No [\[Skip to S10\]](#)

[BANK S9, S10, AND S11 ON SAME SCREEN]**[ASK IF EXPERIENCED COVID-19 SYMPTOMS (S7=1)]**

S9. How many days did you experience symptoms of Covid-19? Please answer from the first day that you experienced any symptoms until you were completely asymptomatic.

[NUMERIC QUESTION]

_____ days **[Range 1-99]**

[ASK ALL CONTINUING RESPONDENTS, S7=1-2]

S10. Did you have a PCR or antibody test of Covid-19? *Select one.*

1. Yes – I tested positive.
2. Yes – I tested negative.
3. No – I did not get a test.
4. No – I did not have access to the test.

[ASK ALL CONTINUING RESPONDENTS, S7=1-2]

S11. **[IF S7=1, SHOW:]** Since Covid-19 symptom onset, did you have a test for influenza or other respiratory viruses? *Select one.*

[IF S7=2, SHOW:] Did you have a test for influenza or other respiratory viruses? *Select one.*

1. Yes – I tested positive.
2. Yes – I tested negative.
3. No – I did not get a test.
4. No – I did not have access to the test.

[BANK S12, S13, S8-ON SAME SCREEN]**[ASK ALL CONTINUING RESPONDENTS, S7=1-2]**

S12. How would you describe your access to personal protective equipment during the Covid-19 pandemic? By personal protective equipment (PPE), we mean masks, face shields, gowns, and gloves. *Select one.*

1. Nonexistent (no access to at least one of the following: masks, face shields, gowns, and gloves)
2. Poor (little access to masks, face shields, gowns, and gloves)
3. Basic (access to at least one daily mask, face shield, gown, and gloves)
4. Good (I had access to a change of mask, gown, and gloves if soiled as well as a face shield)
5. Excellent (I had access to a fresh mask, gown, and gloves every time that I entered a new patient room as well as a face shield)

[ASK SYMPTOMATIC RESPONDENTS, S7=1]

S13. How would you rate the severity of your personal Covid-19 illness? *Select one.*

1. Very Mild: asymptomatic or nearly asymptomatic
2. Mild: symptoms [fever <38°C (without treatment), with or without cough, no dyspnea, no gasping, no abnormal imaging findings]
3. Moderate: [fever, respiratory symptoms, and/or imaging findings of pneumonia]
4. Severe: meet any of the following: 1) respiratory distress, RR ≥30 times/min 2) SpO₂ <93% at rest 3) PaO₂/FiO₂ ≤ 300 mm Hg
5. Critical: Respiratory failure needing mechanical assistance, ICU admission, shock, or extra pulmonary organ failure

[ASK IF EXPERIENCED COVID-19 SYMPTOMS (S7=1)]

S8. Please check off all of the symptoms or diagnoses that you experienced with Covid-19. *Select all that apply.*

**GROUP LIKE-SYMPTOMS TOGETHER IN BLOCKS BUT RANDOMIZE ITEMS WITHIN EACH BLOCK:
1-4, 5-6, 8-10, 11-12, 13-18, 19-24**

RANDOMIZE THE GROUP BLOCKS; ANCHOR CODE 24

1. Cough
2. Fever (subjective or documented)
3. Chills
4. Fatigue
5. Sore throat
6. Muscle aches
7. Headache
8. Nausea
9. Vomiting

10. Diarrhea
11. Loss of taste
12. Loss of smell
13. Shortness of breath
14. Difficulty breathing
15. Abnormal Chest X-ray
16. Low oxygen saturation, SpO₂ <93% at rest
17. Respiratory distress, RR ≥30 times/min
18. Acute lung injury, PaO₂/FiO₂ ≤ 300 mm Hg
19. Respiratory failure, needed mechanical assistance
20. Pulmonary embolus
21. Deep Vein Thrombosis
22. Stroke
23. Shock
24. Heart attack
25. Other (specify: _____)

[X – Covid Exposure Risk]**[ASK ALL]**

NEW

X1 Have you been in close contact with anyone **outside** of your workplace with a confirmed diagnosis of Covid-19 (SARS-CoV2)? *Select one.*

(Face-to-face within 6 feet for ≥ 10 minutes)

1. Yes
2. No
3. Not sure

[BANK X2 and X3 ON SAME SCREEN]**[ASK ALL]**

NEW

X2 Have you been in close contact with any **suspected or confirmed** case of Covid-19 **inside** your workplace while **not wearing** Covid-recommended PPE? *Select one.*

(Face-to-face within 6 feet for ≥ 10 minutes)

1. Yes
2. No
3. Not sure

[ASK ALL]

NEW

X3 Have you been in the room of a **confirmed** Covid-19 patient during any of the following? *Select all that apply*

1. CPAP or BiPAP
2. Nebulization
3. Intubation
4. CPR
5. Other procedure, please specify: _____

[A - Demographic and clinical characteristics]**[BANK A1, A2, A3, A4 ON SAME SCREEN]****[ASK ALL]**

A1. Are you male or female...? *Select one.*

1. Male
2. Female
3. Other
4. Prefer not to say

Source: From NHANES 2017-2018

https://wwwn.cdc.gov/Nchs/Nhanes/2017-2018/DEMO_J.htm

[ASK ALL]

A2. Are you...? *Select one.*

1. Married
2. Divorced
3. Widowed
4. Separated
5. Never married
6. Living with partner
7. Prefer not to say

[ASK ALL]

A3. How many people including yourself live in your household?

1. # of adults age 18+ _____ [DROP DOWN MENU: RANGE 1-12]
2. # of children age 0-17 _____ [DROP DOWN MENU: RANGE 0-12]

[ASK ALL]

A4. Which one or more of the following would you say is your race or ethnicity? *Select all that apply.*

[SHOW SECTION HEADERS IN THIS QUESTION, "White", "Asian / Asian British", etc.]**White**

1. English / Welsh / Scottish / Northern Irish / British
2. Irish
3. Gypsy or Irish Traveler
4. Any other White background

Mixed / Multiple ethnic groups

5. White and Black Caribbean
6. White and Black African
7. White and Asian
8. Any other Mixed / Multiple ethnic background

Asian / Asian British

9. Indian
10. Pakistani
11. Bangladeshi
12. Chinese
13. Any other Asian background

Black / African / Caribbean / Black British

14. African
15. Caribbean
16. Any other Black / African / Caribbean background

17. Other ethnic group
18. Prefer not to say **[EXCLUSIVE]**

[BANK A5, A6, A7, A8 ON SAME SCREEN]**[ASK ALL]**

A5. What is your age in years?

_____ years **[Range 18-99]**

[ASK ALL]

A6. What is your height? **[For US show ft/inches, for EU show cm]**

[NUMERIC RESPONSES]

1. **[EX-US, EX-UK: S0=2-5]** _____ cm **[RANGE: 90-220]**
2. **[US & UK ONLY: S0=1, 6]** _____ ft _____ inches **[RANGE: 3-7 FEET; INCHES: 0-11]**

[ASK ALL]

A7. What is your weight? **[For US show pounds, for EU show kg]**

[NUMERIC RESPONSES]

1. **[EX-US, EX-UK: S0=2-5]** _____ kg **[RANGE: 12-160]**
2. **[US & UK ONLY: S0=1, 6]** _____ pounds **[RANGE: 50-350]**

[ASK ALL]

A8. How would you classify your smoking status? *Select one.*

1. Current smoker
2. Former smoker
3. Never smoked

[B - Medical history and medication history]**[BANK B1, B2 ON SAME SCREEN]****[ASK ALL]**

B1. Have you ever been diagnosed with any of the following medical conditions **prior** to the Covid-19 pandemic? *Select all that apply.*

[ALPHABETIZE LIST]

1. Prediabetes
2. Diabetes
3. High cholesterol
4. Hypertension
5. Cancer
6. Coronary Disease or Heart attack
7. Heart Failure
8. Prior lung disease
9. Prior lung infection
10. Asthma
11. Overweight
12. Autoimmune disease [please specify]
13. Other [please specify] **[ANCHOR]**
14. None of the above **[EXCLUSIVE; ANCHOR]**

[ASK ALL]

B2. Prior to the Covid-19 pandemic, were you taking any of the following medications on a daily basis? *Select all that apply.*

[ALPHABETIZE LIST]

1. Angiotensin-converting enzyme inhibitor (ACEI)
2. Angiotensin receptor blocker (ARB)
3. Statin
4. Metformin
5. Aspirin
6. Ibuprofen
7. Albuterol inhaler
8. Inhaled steroids
9. Oral prednisone
10. Methotrexate
11. Hydroxychloroquine
12. Other [please specify] **[ANCHOR]**
13. None of the above **[EXCLUSIVE; ANCHOR]**

[C - Food frequency questionnaire]**[ASK ALL]**

C1. **Food Set [N] of 5 [ADD TO THIS LABEL TO TOP OF SCREEN FOR EACH PAGE; UPDATE THE COUNTER 'N' ON EACH SCREEN]**

Over the past 12 months prior to the Covid-19 pandemic, how often did you eat or drink 1 serving of each of the following?

Please enter the number of times "Per Week" **OR** the number of times "Per Month". *Select one only per row.*

RESPONDENT CAN SELECT ONE COLUMN PER ROW ONLY. RESPONDENT ALLOWED TO CHOOSE COLUMN 1 IN ONE ROW AND COLUMN 2 IN ANOTHER ROW, OR COLUMN 3 IN ANOTHER ROW.]

	1	2	3
[SHOW SETS IN NUMERIC ORDER – 1-6]	# Servings Per Week [RANGE: 0-99]	# Servings Per Month [RANGE: 0-99]	Never in Past 12 Months [EXCLUSIVE]
[PIPE IN LIST BELOW]	□□ #	□□ #	○

Set 1

1. Milk
2. Yogurt/Yoghurt
28. White or fresh cheese (Burgos, ...) or low-fat cheese
29. Other cheeses: cured or semi-cured, creamy
36. Dairy desserts: custard, flan, cottage cheese
40. Ice creams
3. Chocolate: table, chocolates, "Kit Kat", "Mars", [UK, S0=1: "Cadbury's Dairy Milk"] [FR, DE, SP, IT, DE S0=2-5: "Milka"], [US, S0=6: M&M's]
39. Treats: jelly beans, candy
4. Puffed breakfast cereals ("Corn Flakes", "Kellogg's", [UK, S0=1 4: "Weetabix"] [FR, S0=2: "Miel Pops"], [DE, S0=3: "Vitalis"], [SP, S0=4, "Miel Pops"], [IT, S0=5: "Miel Pops"] [US, S0=6: Cheerios]
5. Sweet cookies and crackers
6. Cookies with chocolate, cream ...
7. Cupcakes, sponge cake ...
37. Chocolate or cream cakes
8. Pastries, donut, croissant

Set 2

9. Salad: lettuce, tomato, endive
10. Green vegetables such as green beans, chard, or spinach
11. Other vegetables, such as eggplants, mushrooms
12. Baked, fried, or boiled potatoes
13. Legumes: lentils, chickpeas, beans ...
16. Soups or cream-based soups
14. White rice, paella
15. Pasta: noodles, macaroni, spaghetti
25. White Bread (in sandwich, with meals, ...)
26. Dark or whole grain bread
24. Croquettes, dumplings, pizza

Set 3

17. Eggs
18. Chicken or turkey
19. Veal, pork, lamb (steak, patty, ...)
20. Minced meat, longaliza, hamburger
27. Salty, sweet ham, sausages
21. White fish: hake, grouper, ...
22. Blue fish: sardines, tuna, salmon, ...
23. Seafood: mussels, prawns, squid, ...
24. [INTENTIONALLY BLANK]
25. [INTENTIONALLY BLANK]
26. [INTENTIONALLY BLANK]

Set 4

17. [INTENTIONALLY BLANK]
18. [INTENTIONALLY BLANK]
19. [INTENTIONALLY BLANK]

Set 4

20. Citrus fruits: orange, tangerine, ...
21. Other fruits, apple, pear, peach, banana ...
22. Canned fruits (in syrup)
23. Natural fruit juices
24. Commercial fruit juices
25. Nuts: peanuts, hazelnuts, almonds
26. [INTENTIONALLY BLANK]
27. [INTENTIONALLY BLANK]
28. Snack bags ([US, S0=6: "chips" / S0=1-5: "potato crisps"], "Cheetos", "Fritos", "~~Lays~~")
29. [INTENTIONALLY BLANK]
30. [INTENTIONALLY BLANK]

Set 5

31. Sugary drinks ("Coca-Cola", "Fanta" ...)
32. Low calorie drinks (diet coke, coca-cola light)
33. Wine, sangria
34. Beer (*not including alcohol-free beer*)
35. Coffee
36. Black or green tea
37. Distilled beverages: whiskey, gin, cognac
38. Vegetable oil (e.g., plant-based oil such as olive oil, corn, canola, or rapeseed oil)
39. Butter

[C - Perception of diet quality]**[BANK C2, C3 ON SAME SCREEN]****[ASK ALL]**

C2. Prior to the Covid-19 pandemic, what percentage of your diet was composed of packaged and processed foods (this includes ready-to-eat meals, packaged foods with chemical additives, colorants, or flavorings)? *Select one.*

1. <25% of total energy intake
2. 25-<50% of total energy intake
3. 50-75% of total energy intake
4. >75% of total energy intake

[ASK ALL]

C3. Prior to the Covid-19 pandemic, for ALL of the past 12 months, have you followed any type of specific diet? *Select all that apply.*

[ALPHABETIZE LIST]

1. Whole foods, plant-based diet
2. Keto
3. Vegetarian diet
4. Mediterranean diet
5. Pescatarian diet
6. Paleo
7. Low fat
8. Low carb
9. High protein
10. Other (specify: _____)
11. None of the above

[ANCHOR]
[EXCLUSIVE; ANCHOR]

[Dietary supplements]

Adapted version of dietary supplement questions from DHQ: [source: https://dceg.cancer.gov/tools/design/questionnaires/non-alcoholic-beverage-food-supplements/diet-history-dietary-supplement-use](https://dceg.cancer.gov/tools/design/questionnaires/non-alcoholic-beverage-food-supplements/diet-history-dietary-supplement-use)

[ASK ALL]

D1. How often do you take **vitamin D**? *Select one.*

1. Never **[go to question D2]**
2. Less than 1 day per month
3. 1-3 days per month
4. 1-3 days per week
5. 4-6 days per week
6. Every day

[BANK D1a, D1b ON SAME SCREEN]**[ASK IF D1=2-6]**

D1a. When you take **vitamin D**, about how much do you take in one day? *Select one.*

1. Less than 1000 IU
2. 1,000-1,499 IU
3. 1,500-1,999 IU
4. 2,000 IU or more
5. Don't know

[ASK IF D1=2-6]

D1b. For how many years have you taken **vitamin D**? *Select one.*

1. Less than 1 year
2. 1-4 years
3. 5-9 years
4. 10 or more years

[ASK ALL]

D2. How often do you take **omega-3 fatty acids or fish oil**? *Select one.*

1. Never **[go to question D3]**
2. Less than 1 day per month
3. 1-3 days per month
4. 1-3 days per week
5. 4-6 days per week
6. Every day

[BANK D2a, D2b ON SAME SCREEN]**[ASK IF D2=2-6]**

D2a. When you take **omega-3 fatty acids or fish oil**, about how much do you take in one day? *Select one.*

1. Less than 100 mg
2. 100-149 mg
3. 150-199 mg
4. 200 mg or more
5. Don't know

[ASK IF D2=2-6]

D2b. For how many years have you taken **omega-3 fatty acids or fish oil**? *Select one.*

1. Less than 1 year
2. 1-4 years
3. 5-9 years
4. 10 or more years

[ASK ALL]

D3. How often do you take **vitamin C**? *Select one.*

1. Never **[go to question D4]**
2. Less than 1 day per month
3. 1-3 days per month
4. 1-3 days per week
5. 4-6 days per week
6. Every day

[BANK D3a, D3b ON SAME SCREEN]**[ASK IF D3=2-6]**

D3a. When you take **vitamin C**, about how much do you take in one day? *Select one.*

1. Less than 500 mg
2. 500-999 mg
3. 1,000- 1,499 mg
4. 1,500-1,999 mg
5. 2,000 mg or more
6. Don't know

[ASK IF D3=2-6]

D3b. For how many years have you taken **vitamin C**? *Select one.*

1. Less than 1 year
2. 1-4 years
3. 5-9 years
4. 10 or more years

[ASK ALL]

D4. How often do you take **cod liver oil**? *Select one.*

1. Never **[go to question D5]**
2. Less than 1 day per month
3. 1-3 days per month
4. 1-3 days per week
5. 4-6 days per week
6. Every day

[BANK D4a, D4b ON SAME SCREEN]**[ASK IF D4=2-6]**

D4a. When you take **cod liver oil**, about how much do you take in one day? *Select one.*

1. Less than 1000 mg
2. 1,000-1,499 mg
3. 1,500-1,999 mg
4. 2,000 mg or more
5. Don't know

[ASK IF D4=2-6]

D4b. For how many years have you taken **cod liver oil**? *Select one.*

1. Less than 1 year
2. 1-4 years
3. 5-9 years
4. 10 or more years

[BANK D5, D6 ON SAME SCREEN]**[ASK ALL]**

D5. Please mark any of the following single supplements you took more than once per week for the 12 months prior to the Covid-19 pandemic. *Select all that apply.*

[Randomize all except other/none]

1. Multivitamin/mineral
2. Folic acid/folate
3. Vitamin A
4. Vitamin B complex
5. Vitamin E
6. Zinc
7. N-acetyl-cysteine
8. Choline
9. Other (specify: _____)
10. None of the above

[ANCHOR]
[EXCLUSIVE; ANCHOR]

[ASK ALL]

D6. Please mark any of the following herbal or botanical supplements you took more than once per week for the 12 months prior to the Covid-19 pandemic. *Select all that apply.*

[Randomize all except other/none]

1. Curcumin
2. Elderberry
3. Echinacea
4. Other (specify: _____)
5. None of the above

[ANCHOR]
[EXCLUSIVE; ANCHOR]

[E - Physical activity]

Source: https://www.cdc.gov/Nchs/Nhanes/2005-2006/PAQIAF_D.htm - PDACTIV

[ASK ALL]

E1. Prior to the Covid-19 pandemic, what activities did you do during a typical week? Please report the frequency and duration of each type of physical activity you did during a typical 7-day period prior to Covid-19.

[ZERO FILL THE GRID TO BEGIN WITH AND ALLOW RESPONDENTS TO CHANGE THE RESPONSES IN THE GRID]

[# FREQUENCY RANGE: 0-14 0-99]

[# DURATION RANGE: 0-360]

		1	2
		Frequency you did during a typical 7-day period prior to Covid-19	Average duration of activity each time
1.	No physical activity	<input type="checkbox"/>	
2.	Aerobics	_____ times	_____ minutes
3.	Baseball	_____ times	_____ minutes
4.	Basketball	_____ times	_____ minutes
5.	Bicycling	_____ times	_____ minutes
6.	Bowling	_____ times	_____ minutes
7.	Boxing	_____ times	_____ minutes
8.	Cheerleading and gymnastics	_____ times	_____ minutes
9.	Dance	_____ times	_____ minutes
10.	Fishing	_____ times	_____ minutes
11.	Football	_____ times	_____ minutes
12.	Frisbee	_____ times	_____ minutes
13.	Gardening	_____ times	_____ minutes
14.	Golf	_____ times	_____ minutes
15.	Hiking	_____ times	_____ minutes
16.	Hockey	_____ times	_____ minutes
17.	Horseback riding	_____ times	_____ minutes
18.	Hunting	_____ times	_____ minutes
19.	Jogging	_____ times	_____ minutes
20.	Kayaking	_____ times	_____ minutes
21.	Martial arts	_____ times	_____ minutes
22.	Push-ups	_____ times	_____ minutes
23.	Racquetball	_____ times	_____ minutes
24.	Rollerblading	_____ times	_____ minutes
25.	Rope jumping	_____ times	_____ minutes
26.	Rowing	_____ times	_____ minutes
27.	Running	_____ times	_____ minutes
28.	Sit-ups	_____ times	_____ minutes
29.	Skateboarding	_____ times	_____ minutes
30.	Skating	_____ times	_____ minutes
31.	Skiing – cross country	_____ times	_____ minutes
32.	Skiing – downhill	_____ times	_____ minutes
33.	Soccer	_____ times	_____ minutes
34.	Softball	_____ times	_____ minutes
35.	Stair climbing	_____ times	_____ minutes

36.	Stretching	_____ times	_____ minutes
37.	Surfing	_____ times	_____ minutes
38.	Swimming	_____ times	_____ minutes
39.	Tennis	_____ times	_____ minutes
40.	Treadmill	_____ times	_____ minutes
41.	Volleyball	_____ times	_____ minutes
42.	Walking	_____ times	_____ minutes
43.	Weight lifting	_____ times	_____ minutes
44.	Wrestling	_____ times	_____ minutes
45.	Yard work	_____ times	_____ minutes
46.	Yoga	_____ times	_____ minutes
47.	Other, specify: _____	_____ times	_____ minutes
48.	Other, specify: _____	_____ times	_____ minutes
49.	Other, specify: _____	_____ times	_____ minutes

[IF-FREQUENCY > 0, THEN MINUTES FOR THAT ACTIVITY MUST BE >0 AS WELL]

[ASK ALL]

E1a. You indicated that you take part in the following physical activities in a typical 7-day period prior to Covid-19. Is this list correct? *Select one.*

Note: if the list is not correct, you will be re-asked the prior question.

[LIST ALL ACTIVITIES IN E1>0 days and 0 minutes]

[E1 ACTIVITY]	[E1 FREQUENCY > 0] times per week	[E1 DURATION > 0] minutes each time
---------------	-----------------------------------	-------------------------------------

1. Yes **[Go to F1]**
2. No **[Go to E1]**

[F - Sleep]**[BANK F1, F2, F3, F4, F5 ON SAME SCREEN]****[ASK ALL]**

F1. Please report the average duration of sleep (in hours) per **night** during the last 12 months prior to the Covid-19 pandemic.

_____ hours **[DROP DOWN MENU: RANGE 1-15]**

[ASK ALL]

F2. Please report the average duration of napping per **daytime hours** during the last 12 months.

_____ hours **[DROP DOWN MENU: RANGE 0-12]**

[ASK ALL]

F3. Prior to the Covid-19 pandemic, did you have difficulties falling asleep at **night**? *Select one.*

1. Yes
2. No

[ASK ALL]

F4. Prior to the Covid-19 pandemic, did you often wake up in the early hours, unable to get back to sleep? *Select one.*

1. Yes
2. No

[ASK ALL]

F5. Prior to the Covid-19 pandemic, did you take sleeping pills more than 3 times per week? *Select one.*

1. Yes
2. No

[G - Stress]**Emotional exhaustion:****[ASK ALL]**

G1. Prior to the Covid-19 pandemic, I felt burned out from my work:
Select one.

1. Never
2. A few times a year or less
3. Once a month or less
4. A few times a month
5. Once a week
6. A few times a week
7. Every day

Source: [10.5116/ijme.5918.ad11](https://doi.org/10.5116/ijme.5918.ad11)

[ASK ALL]

G2. Prior to the Covid-19 pandemic, thinking of your assets, debts, and savings, how satisfied were you with your overall personal financial condition? *Select one.*

Not at all Satisfied				Somewhat Satisfied					Extremely Satisfied
1	2	3	4	5	6	7	8	9	10

[END OF SURVEY]